CMT1A Research Breakthrough!
Scientists at Ionis Pharmaceuticals, in collaboration with the Charcot-Marie-Tooth Association, have identified a promising early-stage therapeutic approach with antisense technology for CMT Type 1A (CMT1A), the most common form of the disease, accounting for half of all cases. Read more …
Breakthroughs to a Cure
Thanks to your support of the CMTA’s research initiative, promising therapeutic approaches for CMT1A have been identified. Studies in two laboratory models of CMT1A not only stopped progression of the disease, but also showed improvement of some symptoms. And, while the 1A project is furthest along the path to drug delivery, projects addressing 90% of all cases of CMT, including types 1B, 1X, 2A, 2E and 4, are also delivering promising results using cutting-edge techniques. To deliver the first treatments for CMT, we need funding for clinical trials and further drug development. Learn more…
Fighting for Claire and Her Generation
Russ Mitchell talks for a living. He’s a sportscaster. But until recently he didn’t talk about his CMT with anyone outside his family. That changed in a big way on September 1, when he added his voice to the chorus of voices spreading the word about CMT for Awareness Month. Read his story…
Studies in two laboratory models of CMT1A not only stopped progression of the disease, but also showed improvement of some symptoms. To deliver the first treatments for CMT1A and other types of CMT, we need funding for clinical trials and further drug development.
Charcot-Marie-Tooth, or CMT, is the most commonly inherited peripheral neuropathy and affects an estimated 2.8 million people.
The CMTA has over 80 Branches across North America to support people with CMT, raise awareness, and fund research. Connect with your nearest Branch today!
Without fundraising and community volunteers, the CMTA would not be the leading force in CMT Research that it is today. Are you ready to make an impact?
Visit our store to see some of the most fun and fashionable ways to raise awareness!